Canada green-lights InSightec's ablation system

August 22, 2013 by Sony Salzman

Canadian regulators give InSightec a nod of approval for the ExAblate system to treat benign uterine tumors and painful metastatic bone tumors.

Canada green-lights InSightec's ablation system

Canadian healthcare regulators approved InSightec's ExAblate ultrasound system, clearing the device for use against 2 different diseases. Health Canada granted ExAblate indication to break up benign uterine tumors and to alleviate painful symptoms of metastatic bone tumors.

The Tirat Carmel, Israel-based company specializes in ultrasound ablation technology. InSightec's ExAblate uses a highly focused beam, guided by an MRI, to break up tissue. The tumor-busting procedure uses non-iodizing radiation and alleviates symptoms without surgical removal.

Sign up to get our free newsletters delivered right to your inbox.

The ExAblate device has won different indications in different markets around the world, indicated to treat bone tumors, brain disorders, uterine fibroids, uterine thickening and to help with pain management.

In 2012, ExAblate was cleared in the U.S. to treat pain-inducing bone tumors, and last month Chinese regulators cleared the device for uterine solid-tumor treatment.